-

Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will participate in Craig-Hallum’s 18th Annual Institutional Investor Conference on Wednesday, June 2, 2021.

Each year, Craig-Hallum hosts a multi-industry investor conference in Minneapolis featuring over 150 public companies where institutional clients can meet formally with corporate management. This year’s conference will be virtual and consists of one-on-one conference calls of 30-minutes’ duration. Attendance is by invitation only. For more information about the conference or to inquire about scheduling a one-on-one meeting with Mr. O’Connor, please contact Hayden IR at slp@haydenir.com.

About Simulations Plus, Inc.

Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report.

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
(661) 723-7723
renee@simulations-plus.com

Hayden IR
Mr. Brian S. Siegel, IRC®, M.B.A.
(346) 396-8696
slp@haydenir.com

Simulations Plus, Inc.

NASDAQ:SLP

Release Summary
Simulations Plus CEO Shawn O'Connor will participate in Craig-Hallum's 18th Annual Institutional Investor Conference on June 2, 2021.
Release Versions

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
(661) 723-7723
renee@simulations-plus.com

Hayden IR
Mr. Brian S. Siegel, IRC®, M.B.A.
(346) 396-8696
slp@haydenir.com

Social Media Profiles
More News From Simulations Plus, Inc.

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active therapeutic development program. The collaboration will evaluate how AI-enabled...

Simulations Plus Announces Completion of Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations...

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology...
Back to Newsroom